drugset / Trial / NCT03316976

A Study to Evaluate the Pharmacokinetics of Dexlansoprazole 30 Milligram (mg) and 60 mg Delayed-release Capsules in Healthy Chinese Participants

NCT03316976

Phase 1 Completed 40 enrolled Takeda
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to assess the pharmacokinetics after a single dose of dexlansoprazole 30 and 60 mg delayed-release capsules in healthy Chinese participants.

Timeline

Start
2017-11-22
Primary completion
2018-02-08
Completion
2018-02-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Dexlansoprazole Other / unclassified 30 mg Oral
Subject Dexlansoprazole Other / unclassified 60 mg Oral

Indications

No indication recorded.